BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 254 filers reported holding BRIDGEBIO PHARMA INC in Q4 2023. The put-call ratio across all filers is 1.26 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $388,958 | +53.3% | 14,750 | 0.0% | 0.05% | +56.2% |
| Q2 2023 | $253,700 | +3.7% | 14,750 | 0.0% | 0.03% | -3.0% |
| Q1 2023 | $244,555 | -26.2% | 14,750 | -66.1% | 0.03% | -34.0% |
| Q4 2022 | $331,470 | -28.7% | 43,500 | -6.9% | 0.05% | -35.1% |
| Q3 2022 | $465,000 | -1.7% | 46,737 | -10.3% | 0.08% | +1.3% |
| Q2 2022 | $473,000 | -10.6% | 52,087 | 0.0% | 0.08% | 0.0% |
| Q1 2022 | $529,000 | -39.1% | 52,087 | 0.0% | 0.08% | -46.5% |
| Q4 2021 | $869,000 | -64.5% | 52,087 | -0.4% | 0.14% | -75.2% |
| Q3 2021 | $2,451,000 | -23.1% | 52,287 | 0.0% | 0.57% | -23.3% |
| Q2 2021 | $3,187,000 | +91.4% | 52,287 | +2.4% | 0.75% | +20.9% |
| Q2 2020 | $1,665,000 | +720.2% | 51,044 | +780.1% | 0.62% | +713.2% |
| Q4 2019 | $203,000 | – | 5,800 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $60,317,000 | 40.05% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $308,746,000 | 6.20% |
| M28 Capital Management LP | 513,300 | $5,102,000 | 5.33% |
| GREAT POINT PARTNERS LLC | 1,050,000 | $10,437,000 | 2.51% |
| Octagon Capital Advisors LP | 933,743 | $9,281,000 | 1.60% |
| HHLR ADVISORS, LTD. | 5,362,014 | $53,298,000 | 1.40% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $264,613,000 | 1.22% |
| Cormorant Asset Management, LP | 1,469,179 | $14,604,000 | 1.02% |
| Fernwood Investment Management, LLC | 204,550 | $2,033,000 | 0.86% |
| TANG CAPITAL MANAGEMENT LLC | 585,424 | $5,819,000 | 0.71% |